Indomethacin-guided cancer selective prodrug conjugate activated by histone deacetylase and tumour-associated protease

Joo Hee Jang; Hoyeon Lee; Amit Sharma; Sang Min Lee; Tae Hoon Lee; Chulhun Kang; Jong Seung Kim

doi:10.1039/c6cc04255d

Indomethacin-guided cancer selective prodrug conjugate activated by histone deacetylase and tumour-associated protease

Joo Hee Jang, Hoyeon Lee, Amit Sharma, Sang Min Lee, Tae Hoon Lee, Chulhun Kang, Jong Seung Kim

Research output: Contribution to journal › Article › peer-review

33 Citations (Scopus)

Abstract

An indomethacin-guided drug delivery conjugate (IGDDC) has been designed by utilizing cancer associated elevated HDAC and CTSL activities as consecutive demasking ventures for drug activation. IGDDC exhibited preferential uptake by COX-2 positive cells both in vitro and ex vivo highlighting indomethacin's role in designing new cancer-specific drug delivery frameworks.

Original language	English
Pages (from-to)	9965-9968
Number of pages	4
Journal	Chemical Communications
Volume	52
Issue number	64
DOIs	https://doi.org/10.1039/c6cc04255d
Publication status	Published - 2016

ASJC Scopus subject areas

Catalysis
Electronic, Optical and Magnetic Materials
Ceramics and Composites
Chemistry(all)
Surfaces, Coatings and Films
Metals and Alloys
Materials Chemistry

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1039/c6cc04255d

Cite this

@article{d5d73e98e804461a933a2ad684bddcc3,

title = "Indomethacin-guided cancer selective prodrug conjugate activated by histone deacetylase and tumour-associated protease",

abstract = "An indomethacin-guided drug delivery conjugate (IGDDC) has been designed by utilizing cancer associated elevated HDAC and CTSL activities as consecutive demasking ventures for drug activation. IGDDC exhibited preferential uptake by COX-2 positive cells both in vitro and ex vivo highlighting indomethacin's role in designing new cancer-specific drug delivery frameworks.",

author = "Jang, {Joo Hee} and Hoyeon Lee and Amit Sharma and Lee, {Sang Min} and Lee, {Tae Hoon} and Chulhun Kang and Kim, {Jong Seung}",

note = "Funding Information: This work was supported by CRI (No. 2009-0081566, JSK), NRF (No. 2015R1A5A1037656, CK), the Basic Science Research Program (No. 20100020209, CK) project grants fromthe National Research Foundation of Korea. Publisher Copyright: {\textcopyright} 2016 The Royal Society of Chemistry.",

year = "2016",

doi = "10.1039/c6cc04255d",

language = "English",

volume = "52",

pages = "9965--9968",

journal = "Chemical Communications",

issn = "1359-7345",

publisher = "Royal Society of Chemistry",

number = "64",

}

TY - JOUR

T1 - Indomethacin-guided cancer selective prodrug conjugate activated by histone deacetylase and tumour-associated protease

AU - Jang, Joo Hee

AU - Lee, Hoyeon

AU - Sharma, Amit

AU - Lee, Sang Min

AU - Lee, Tae Hoon

AU - Kang, Chulhun

AU - Kim, Jong Seung

N1 - Funding Information: This work was supported by CRI (No. 2009-0081566, JSK), NRF (No. 2015R1A5A1037656, CK), the Basic Science Research Program (No. 20100020209, CK) project grants fromthe National Research Foundation of Korea. Publisher Copyright: © 2016 The Royal Society of Chemistry.

PY - 2016

Y1 - 2016

N2 - An indomethacin-guided drug delivery conjugate (IGDDC) has been designed by utilizing cancer associated elevated HDAC and CTSL activities as consecutive demasking ventures for drug activation. IGDDC exhibited preferential uptake by COX-2 positive cells both in vitro and ex vivo highlighting indomethacin's role in designing new cancer-specific drug delivery frameworks.

AB - An indomethacin-guided drug delivery conjugate (IGDDC) has been designed by utilizing cancer associated elevated HDAC and CTSL activities as consecutive demasking ventures for drug activation. IGDDC exhibited preferential uptake by COX-2 positive cells both in vitro and ex vivo highlighting indomethacin's role in designing new cancer-specific drug delivery frameworks.

UR - http://www.scopus.com/inward/record.url?scp=84982693879&partnerID=8YFLogxK

U2 - 10.1039/c6cc04255d

DO - 10.1039/c6cc04255d

M3 - Article

C2 - 27440001

AN - SCOPUS:84982693879

SN - 1359-7345

VL - 52

SP - 9965

EP - 9968

JO - Chemical Communications

JF - Chemical Communications

IS - 64

ER -

Indomethacin-guided cancer selective prodrug conjugate activated by histone deacetylase and tumour-associated protease

Abstract

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this